

## **REMARKS**

Claims 1-133 appear in this application for the Examiner's review and consideration.

Applicants have amended the specification to correct typographical errors. Support for the amendment on page 52, beginning on line 33, and ending on page 53, line 3 can be found, e.g., on page 19, line 2 of the originally filed specification. Support for the amendment on page 53, beginning on line 4 and ending on line 6, can be found, e.g., on page 19, line 4 of the originally filed specification. Support for the amendment on page 57, beginning on line 5 and ending on line 9, can be found, e.g., on page 22, line 2 of the originally filed specification. Support for the amendment on page 57, beginning on line 10 and ending on line 12, can be found, e.g., on page 22, line 4 of the originally filed specification. No new matter has been added by these amendments.

## **RESPONSE TO RESTRICTION REQUIREMENT:**

The Examiner has required election to one of the following groups of claims:

- I. Claims 1-19, 96, 101, 106, 111-113 and 126-133, drawn to compounds, compositions and methods of use in connection with Formula I or Formula VI where Ar<sub>1</sub> is pyridine;
- II. Claims 20-38, 97, 102, 107, 114-116 and 126-133, drawn to compounds, compositions and methods of use in connection with Formula II or Formula VI where Ar<sub>1</sub> is pyrazine;
- III. Claims 39-57, 98, 103, 108, 117-119 and 126-133, drawn to compounds, compositions and methods of use in connection with Formula III or Formula VI where Ar<sub>1</sub> is pyrimidine;
- IV. Claims 58-76, 99, 104, 109, 120-122 and 126-133, drawn to compounds, compositions and methods of use in connection with Formula IV or Formula VI where Ar<sub>1</sub> is pyridazine; and
- V. Claims 77-95, 100, 105, 110 and 123-133, drawn to compounds, compositions and methods of use in connection with Formula V or Formula VI where Ar<sub>1</sub> is thiadiazole.

Applicants respectfully point out that claim 127 recites a compound of Formula (VII), which is not mentioned in any of Groups I. through V.; therefore claim 127, and claims 129, 131 and 133 dependent therefrom, appear to be exempted from the restriction requirement.

Applicants hereby elect with traverse claims 1-19, 96, 101, 106, 111-113 and 126-133, the subject matter of Group I. Applicants fully reserve the right to prosecute the subject matter of the non-elected claims in related applications.

Other than the fee for the petition to extend time to respond to the Office communication, no fee is believed to be due for this response. Should any fee be required, please charge such fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

*Samuel B. Abrams by  
George A. Smith 42,140*

Date: September 23, 2005

Samuel B. Abrams

(Reg. No. 30,605)

**JONES DAY**

222 East 41st Street

New York, New York 10017

(212) 326-3939